Robert, on Giroir my story comes from a former Xomite (not Harmon), and his (biased?, selective?, accurate?) recollection is that Giroir learned of Xoma's involvement with BPI and approached Xoma to convince them to let him use it for meningoccemia (sp?).
The FDA stuff has been discussed in other threads by the usual suspects (chirodoc, Andy, etc); yes, it is good, especially if the drug works.
On IDEC, Hecht of Merryl-Lynch thinks Rituxan (and Y2B8; the mouse, radiolabeled version) has a market potential of over $500 mill per year.
Thanks for the other information,
PB |
